Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pharmacokinetic study of the oral formulation of PL-8177

Trial Profile

A pharmacokinetic study of the oral formulation of PL-8177

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PL 8177 (Primary)
  • Indications Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Palatin Technologies
  • Most Recent Events

    • 04 Apr 2019 Primary endpoint has been met. (Release of polymer-bound PL-8177 in the lower gastrointestinal tract after oral administration)
    • 04 Apr 2019 Positive top line results published in the Palatin Technologies Media Release
    • 12 Feb 2019 according to a Palatin Technologies media release, this trial was started during the quarter ended December 31, 2018, with data expected in the first quarter of calendar year 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top